Abstract
CRISPR base editing screens are powerful tools for studying disease-associated variants at scale. However, the efficiency and precision of base editing perturbations vary, confounding the assessment of variant-induced phenotypic effects. Here, we provide an integrated pipeline that improves the estimation of variant impact in base editing screens. We perform high-throughput ABE8e-SpRY base editing screens with an integrated reporter construct to measure the editing efficiency and outcomes of each gRNA alongside their phenotypic consequences. We introduce BEAN, a Bayesian network that accounts for per-guide editing outcomes and target site chromatin accessibility to estimate variant impacts. We show this pipeline attains superior performance compared to existing tools in variant classification and effect size quantification. We use BEAN to pinpoint common variants that alter LDL uptake, implicating novel genes. Additionally, through saturation base editing of LDLR, we enable accurate quantitative prediction of the effects of missense variants on LDL-C levels, which aligns with measurements in UK Biobank individuals, and identify structural mechanisms underlying variant pathogenicity. This work provides a widely applicable approach to improve the power of base editor screens for disease-associated variant characterization.
Competing Interest Statement
L.P. has financial interests in Edilytics, Inc. and SeQure Dx, Inc. L.P.'s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. The remaining authors declare no competing interests.
Funding Statement
The authors thank Grigoriy Losyev and Allison James for technical assistance and funding from UM1HG012010 (R.I.S., L.P.), 1R01HL164409 (C.A.C., R.I.S., L.P.), 1R01GM143249 (R.I.S.), R01HG010372 (C.A.C., T.Y.), American Cancer Society (R.I.S.), American Heart Association (R.I.S.), National Organization for Rare Diseases (R.I.S.), 1R35HG010717-01 (L.P.), National Health and Medical Research Council of Australia (GNT1174405; D.B.A. and Y.Z.), and the Victorian Government's Operational Infrastructure Support Program (Y.Z. and D.B.A.). We are indebted to the UK Biobank and its participants (UK Biobank application #41250 and IRB protocol 2020P002093). We thank Qian Qin, Cameron Smith, and Logan Blaine for help on BEAN model implementation and representation, Kendell Clement for advice on CRISPResso2 usage, Zain Patel for insights on transcription factor binding analysis, Soojung Yang for advice in structural analysis, and Hanna Boen for helping endogenous editing comparison.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We make use of data from the UK Biobank for this analysis, performed under UK Biobank application #41250 and Mass General Brigham IRB protocol 2020P002093.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
